XGES:LSE:LSE-Xtrackers MSCI Genomic Healthcare Innovation UCITS ETF 1C USD Acc GBP (GBP)

ETF | Others |

Last Closing

USD 23.3525

Change

+0.10 (+0.41)%

Market Cap

N/A

Volume

464.00

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

-0.50 (-0.22%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+3.06 (+2.24%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.12 (+0.67%)

USD 562.96B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.06 (+0.46%)

USD 562.96B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

+0.30 (+0.48%)

USD 266.08B
0QZO:LSE 0QZO

+0.30 (+0.27%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.22 (+0.75%)

USD 211.57B
0QZ3:LSE Qualcomm Inc.

-0.21 (-0.13%)

USD 202.26B
0R24:LSE Intel Corp.

+0.24 (+1.20%)

USD 196.14B

ETFs Containing XGES:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.71% 25% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.71% 21% F 36% F
Trailing 12 Months  
Capital Gain 2.07% 35% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 2.07% 29% F 41% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -1.28% 18% F 29% F
Dividend Return -1.28% 17% F 29% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 11.69% 60% D- 76% C+
Risk Adjusted Return -10.92% 17% F 27% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.